One Battle After Another has the best cinematic representation of gel electrophoresis ever, hands down.
02.10.2025 14:41 β π 0 π 0 π¬ 0 π 0@mebrown4.bsky.social
Assistant Professor. Pluripotent stem cell biology and transplantation immunology researcher at UW-Madison. Likes/follows are not endorsements. https://www.linkedin.com/in/matthew-brown-4669a42/
One Battle After Another has the best cinematic representation of gel electrophoresis ever, hands down.
02.10.2025 14:41 β π 0 π 0 π¬ 0 π 0I encourage everyone in academic science to read these proposed rules and comment on them per the instructions on the Federal Register. www.federalregister.gov/documents/20...
29.08.2025 12:34 β π 1 π 0 π¬ 0 π 0Thanks to Sayandeep Saha, Brown Lab Team members, our collaborators, and funding agencies (this wouldnβt have been possible without the NIH!) #NIH @warfnews.bsky.socialβ¬ βͺ
@uwmadisonstemcell.bsky.socialβ¬
@wiscsurgery.bsky.socialβ¬
@morgridgeinstitute.bsky.socialβ¬
www.the-brown-lab.com
We believe ICAM-1 KO PSC will serve as a platform technology, with applications in a number of disease areas. We are looking to collaborate with researchers investigating Parkinsonβs, macular degeneration, and hematopoietic and other contexts that require MHC-replete cells.
12.08.2025 18:10 β π 1 π 0 π¬ 1 π 0ICAM-1 plays an important role in T1D pathogenesis, and we are eager to explore ICAM-1 KO PSC-islets as a new therapeutic candidate for T1D. pubmed.ncbi.nlm.nih.gov/37619906/
12.08.2025 18:10 β π 1 π 0 π¬ 1 π 0Our lab is exploring ICAM-1 KO PSCs for cardiovascular disease, as well as Type 1 diabetes (T1D). T1D is a particularly promising area for leveraging this hypoimmune technology, in light of recent clinical advances. www.nejm.org/doi/full/10....
12.08.2025 18:10 β π 1 π 0 π¬ 1 π 0Conventional hypoimmune PSC editing (e.g., MHC KO) can result in an adverse effectβNK cell missing self killing. Our editing approach leaves MHC intact, so we may avoid this adverse effect. Future studies in our lab will explore the role of NK cells against ICAM-1 KO cells.
12.08.2025 18:10 β π 1 π 0 π¬ 1 π 0ICAM-1 is a target involved in multiple aspects of the allograft rejection response, such as 1) immune synapse formation; 2) transendothelial migration; 3) cellular responses to external inflammatory oxidative stress. We are actively exploring these and other roles of ICAM-1 in our lab.
12.08.2025 18:10 β π 2 π 0 π¬ 1 π 0Use of the NeoThy is important for PSC immunogenicity studies, as other humanized mouse models besides the NeoThy and BLT lack human thymus incorporation and are suboptimal for assessing human MHC-restricted T cell responses. pubmed.ncbi.nlm.nih.gov/32588980/ pubmed.ncbi.nlm.nih.gov/37386161/
12.08.2025 18:10 β π 1 π 0 π¬ 1 π 0We transplanted ICAM-1 KO into next-generation NeoThy humanized mice and saw that the KO cells were retained, but wild type cells were dramatically reduced in size, indicating that the KOs are protected against allograft rejection in vivo.
12.08.2025 18:10 β π 0 π 0 π¬ 1 π 0ICAM-1 KO reduced binding of adaptive (e.g., T cells) and innate (e.g., neutrophils) immune cells. It also resulted in markedly diminished T cell activation and proliferation in vitro.
12.08.2025 18:10 β π 1 π 0 π¬ 1 π 0We successfully and reproducibly made three ICAM-1 knock out cardiovascular cell types (endothelial cells, cardiomyocytes, and cardiac fibroblasts) from multiple PSC lines, including induced PSCs and embryonic stem cells.
12.08.2025 18:10 β π 0 π 0 π¬ 1 π 0ICAM-1 is expressed on endothelial and other cells and is upregulated in response to post-transplantation inflammatory stimuli (e.g., TNFa, IFNg). There are cell surface and secreted forms of ICAM-1. Our KO prevented both types of protein from being expressed by the cells.
12.08.2025 18:10 β π 1 π 0 π¬ 1 π 0This work describes a new class of hypoimmune gene edit for pluripotent stem cell (PSC)-based therapies. We used CRISPR-Cas9 gene editing technology to knock out (KO) ICAM-1, an important cell adhesion molecule used by adaptive and innate immune cells mediating transplantation rejection.
12.08.2025 17:59 β π 1 π 0 π¬ 1 π 0Iβm excited to share our new manuscript in Nature Communications, Saha et al., β Diminished immune cell adhesion in hypoimmune ICAM-1 knockout human pluripotent stem cells.β rdcu.be/eAnEC
12.08.2025 17:58 β π 6 π 2 π¬ 2 π 0Wisconsin is about to get smoked www.washingtonpost.com/weather/2025...
30.05.2025 10:22 β π 1 π 0 π¬ 0 π 0RIP Val Kilmer, one of the greats.
www.nytimes.com/2025/04/01/m...
Underrepresentation of certain ethnic groups in biomedical research is a real problem. See: nap.nationalacademies.org/catalog/2647...
In recent years, the NIH and others have made efforts to address this. Will this important issue become a causualty of the ongoing anti-DEI efforts?
HA
"That sounds bad. But 60 times 7,000 is not 42,000. It is 420,000. This is what Joe Schwarcz noticed. The estimated exposure is not even a tenth of the reference dose. That does not sound as bad."
On black plastic spatulas, and scientific mistakes
nationalpost.com/news/canada/...
Bluesky skeets, not Twitter tweets.
28.11.2024 13:50 β π 1 π 0 π¬ 0 π 0